Related Experiment Video
Updated: Jun 16, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS)
P Ryvlin1, R Kälviäinen, F Von Raison
1CTRS-INSERM IDEE, U821, Université Claude Bernard Lyon 1 and Neurological Hospital, Hospices Civils de Lyon, Lyon, France. ryvlin@cermep.fr
European Journal of Neurology
|February 2, 2010
Summary
This study shows pregabalin effectively reduced seizure frequency in adults with refractory epilepsy. Pregabalin was well-tolerated, with an adverse event profile consistent with prior trials.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Refractory epilepsy poses a significant treatment challenge.
- Controlled trials indicate pregabalin's efficacy as adjunctive therapy.
Purpose of the Study:
- To evaluate the efficacy and tolerability of pregabalin in adults with inadequately controlled partial seizures.
- To assess pregabalin's effectiveness as an add-on treatment in a real-world setting.
Main Methods:
- Open-label, 21-week study involving 476 adult patients.
- Patients received pregabalin (150-600 mg/day) with inadequate seizure control on 1-3 antiepileptic drugs.
- Primary endpoint: mean percentage change in 28-day seizure frequency from baseline.
Main Results:
- A mean seizure frequency reduction of 36% was observed.
- 39% of patients achieved a ≥50% reduction in seizure frequency.
- Common adverse events included dizziness, somnolence, and weight increase.
Conclusions:
- Open-label pregabalin treatment demonstrated efficacy consistent with controlled trials in refractory epilepsy.
- Pregabalin was well-tolerated in this patient population.
- The observed adverse event profile aligns with previous findings.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:19Seizures ll: Types
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...